Royal London Asset Management Ltd. Has $46.99 Million Position in Bruker Corporation $BRKR

Royal London Asset Management Ltd. lessened its position in shares of Bruker Corporation (NASDAQ:BRKR) by 2.0% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 780,857 shares of the medical research company’s stock after selling 16,195 shares during the period. Royal London Asset Management Ltd. owned approximately 0.51% of Bruker worth $46,992,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also made changes to their positions in BRKR. Los Angeles Capital Management LLC acquired a new position in Bruker during the fourth quarter valued at approximately $26,000. Global Retirement Partners LLC acquired a new stake in shares of Bruker in the 2nd quarter valued at $38,000. Parallel Advisors LLC increased its stake in shares of Bruker by 121.0% in the 4th quarter. Parallel Advisors LLC now owns 875 shares of the medical research company’s stock valued at $41,000 after purchasing an additional 479 shares during the last quarter. Allworth Financial LP increased its stake in shares of Bruker by 40.6% in the 3rd quarter. Allworth Financial LP now owns 890 shares of the medical research company’s stock valued at $29,000 after purchasing an additional 257 shares during the last quarter. Finally, Essential Partners LLC acquired a new position in shares of Bruker during the 1st quarter worth $36,000. Institutional investors and hedge funds own 79.52% of the company’s stock.

Bruker Price Performance

BRKR stock opened at $57.08 on Friday. The company has a market capitalization of $8.70 billion, a P/E ratio of -81.54, a PEG ratio of 1.75 and a beta of 1.28. The company has a fifty day moving average price of $58.77 and a 200-day moving average price of $48.00. The company has a debt-to-equity ratio of 0.76, a quick ratio of 0.92 and a current ratio of 1.85. Bruker Corporation has a 52-week low of $28.53 and a 52-week high of $65.30.

Bruker (NASDAQ:BRKR) last issued its quarterly earnings data on Tuesday, August 4th. The medical research company reported $0.49 earnings per share for the quarter, topping the consensus estimate of $0.38 by $0.11. The company had revenue of $838.50 million for the quarter, compared to analysts’ expectations of $853.57 million. Bruker had a negative net margin of 2.35% and a positive return on equity of 12.47%. Bruker’s revenue for the quarter was up 5.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.32 earnings per share. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. As a group, equities analysts expect that Bruker Corporation will post 2.12 EPS for the current year.

Bruker Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, October 7th. Shareholders of record on Monday, September 21st will be given a $0.05 dividend. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.4%. The ex-dividend date is Monday, September 21st. Bruker’s payout ratio is -28.57%.

Wall Street Analyst Weigh In

Several analysts recently weighed in on BRKR shares. Stifel Nicolaus set a $50.00 price objective on Bruker in a research note on Wednesday, August 5th. Barclays boosted their target price on Bruker from $53.00 to $60.00 and gave the stock an “overweight” rating in a research note on Wednesday, June 24th. JPMorgan Chase & Co. increased their target price on shares of Bruker from $55.00 to $65.00 and gave the stock an “overweight” rating in a report on Monday, June 8th. Wall Street Zen upgraded shares of Bruker from a “hold” rating to a “buy” rating in a research note on Saturday, May 9th. Finally, TD Cowen reaffirmed a “hold” rating on shares of Bruker in a report on Wednesday, July 15th. Two investment analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, four have given a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, Bruker presently has an average rating of “Moderate Buy” and a consensus price target of $56.64.

Bruker Profile

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.